Trio Pharmaceuticals
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Trio Pharmaceuticals firmographics
Firmographics- Name
- Trio Pharmaceuticals
- Legal name
- Trio Pharmaceuticals Inc.
- Website
- https://triopharmaceuticals.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Trio Pharmaceuticals industry classification
Industry- Product category
- Cancer Therapeutics / Oncology Biologics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industries
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Trio Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Trio Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Drug Development and Licensing: Pre-revenue biotechnology company developing novel cancer therapeutics. Expected to generate revenue through licensing deals with large pharmaceutical companies, acquisition, or eventual product commercialization upon FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Trio Pharmaceuticals product offering
Product offeringCore offering
Trio Pharmaceuticals develops novel dual-targeting antibody drugs for cancer treatment through two proprietary platforms: TIE-ADC™, a first-ever dual-targeting antibody-drug conjugate that simultaneously kills cancer cells and immunosuppressor cells, and TRAILBody™, an antibody that directly kills cancer cells by activating endogenous cell death while sparing normal cells. The company's pipeline targets hematologic malignancies (AML, MDS) and solid tumors (ovarian, endometrial, TNBC, NSCLC) and is intended to be advanced through clinical development and commercialized via licensing or acquisition by larger pharmaceutical companies.
Product overview
Trio Pharmaceuticals is developing a portfolio of novel dual-action antibody drugs for cancer treatment. The core products are TRAILBody™ (which directly induces cancer cell death via endogenous pathways without toxicity) and TIE-ADC™ (a dual-targeting antibody-drug conjugate that eliminates both tumor cells and immunosuppressor cells). The company is advancing clinical candidates for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), ovarian cancer, endometrial cancer, triple negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).
Differentiator
Problem solved
Functional benefit
Brands
- TIE-ADC: Tumor Immunity Enhancing Antibody-Drug Conjugate - a first-ever dual targeting ADC that kills both cancer cells and immunosuppressor cells to completely remove immunosuppression in tumors.
- TRAILBody
- TRIObody
- TDC
Products and services
- TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate™)
Quantifiable outcome
- Proof-of-concept demonstrated in animal studies
Companies that use Trio Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
Trio Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Trio Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ajinomoto Bio-Pharma ServicescoreDevelopment collaboration to evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Ajinomoto Bio-Pharma Services, for the development of TRIObody Drug Conjugates (TDCs). This partnership enables site-specific conjugation for TRIO's dual-action antibody therapy platform.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Trio Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor targeting with immune activation in the tumor microenvironment — the closest mechanistic analog to Trio's TIE-ADC™ dual-targeting concept of killing cancer cells plus immunosuppressor cells.
- Mersana Therapeutics: Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary payload and conjugation chemistries. Highly comparable pre-clinical/early-clinical stage and indication breadth in oncology.
- Zymeworks: Clinical-stage biotech with proprietary bispecific antibody platforms (Azymetric™) targeting oncology indications. Directly comparable as a platform bispecific antibody developer pursuing partnerships with large pharma.
- MacroGenics: Clinical-stage biotech developing bispecific antibodies (DART® and TRIDENT® platforms) for cancer, including hematologic malignancies and solid tumors. Comparable bispecific mechanism, oncology focus, and partnership-driven business model.
- Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies. Similar stage, similar modality mix (ADCs + immuno-oncology), and similar licensing-out business model targeting large pharma partnerships.
Broad incumbents
- ImmunoGen: Established ADC pioneer (Elahere/Mirvetuximab) acquired by AbbVie. Comparable as an oncology ADC specialist; broader portfolio and commercial-stage assets make it an incumbent peer rather than a direct head-to-head competitor.
- Genmab: Leading bispecific antibody platform company (DuoBody®, HexaBody®) with multiple approved and clinical-stage assets and broad large-pharma partnerships. A broad incumbent rather than a direct competitor; represents the strategic benchmark for bispecific platforms.
Emerging players
- ProfoundBio: Clinical-stage biotech developing next-generation ADCs (including topoisomerase-based payloads) with proprietary conjugation technology. Closely overlapping ADC modality and similar stage/profile to Trio's TIE-ADC program.
- Duality Biologics: Clinical-stage developer of next-generation ADCs with proprietary payload and linker chemistry. Emerging peer with overlapping modality, comparable early-clinical stage, and partnership-heavy business model.
- CytomX Therapeutics: Clinical-stage oncology biotech with Probody® masked antibody platform designed to improve tumor selectivity. Comparable in modality (engineered antibodies for cancer) and partnership-driven development model; complementary rather than head-to-head with TRIO's dual-action approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Trio Pharmaceuticals social profiles
Digital presenceTrio Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trio Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Trio Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trio Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trio Pharmaceuticals
What does Trio Pharmaceuticals do?
Trio Pharmaceuticals develops novel dual-targeting antibody drugs for cancer treatment through two proprietary platforms: TIE-ADC™, a first-ever dual-targeting antibody-drug conjugate that simultaneously kills cancer cells and immunosuppressor cells, and TRAILBody™, an antibody that directly kills cancer cells by activating endogenous cell death while sparing normal cells. The company's pipeline targets hematologic malignancies (AML, MDS) and solid tumors (ovarian, endometrial, TNBC, NSCLC) and is intended to be advanced through clinical development and commercialized via licensing or acquisition by larger pharmaceutical companies.
Is Trio Pharmaceuticals a public or private company?
Trio Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Trio Pharmaceuticals founded?
Trio Pharmaceuticals was founded in 2020. It employs 1 to 10 people.
Where is Trio Pharmaceuticals based?
Trio Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
How does Trio Pharmaceuticals make money?
One revenue line is on record: drug Development and Licensing.
Who are Trio Pharmaceuticals's main competitors?
Direct peers on record are Bolt Biotherapeutics, Mersana Therapeutics, Zymeworks, MacroGenics and Pyxis Oncology. Broad incumbents are ImmunoGen and Genmab. Emerging players are ProfoundBio, Duality Biologics and CytomX Therapeutics.
Does Trio Pharmaceuticals have an API?
No public API is recorded for Trio Pharmaceuticals.
What industry is Trio Pharmaceuticals in?
Trio Pharmaceuticals's product category is Cancer Therapeutics / Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 2836.